Edgar Filing: Torley Helen - Form 4

Torley Helen											
Form 4 February 16, 201	8										
FORM 4			CECU		ND EV	CILA	NCE	COMMESION	т	PPROVAL	
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. <i>See</i> Instruction 1(b).	Filed pur Section 17(UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940							Number: Expires: Estimated burden hou response	urs per	
(Print or Type Respo	onses)										
1. Name and Address of Reporting Person <u>*</u> Torley Helen			2. Issuer Name and Ticker or Trading Symbol HALOZYME THERAPEUTICS INC [HALO]				-	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) C/O HALOZYM THERAPEUTIC SORRENTO VA	ИЕ CS, INC., 11			of Earliest Tr Day/Year) 2018	ransaction			X Director X Officer (giv below) Pre		% Owner her (specify	
			4. If Amendment, Date Original Filed(Month/Day/Year)					 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 			
	(State)	(Zip)	Tak	lo I Non I	Dominatina	Same	itian A		f or Donoficio	lly Owned	
1.Title of 2. Tr	1. Title of2. Transaction Date2A. DeemedSecurity(Month/Day/Year)Execution Date, in		ed Date, if	ble I - Non-Derivative Securities A 3. 4. Securities TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5) (A) or Code V Amount (D) Price			5. Amount of Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect		
Reminder: Report of	n a separate line	e for each cl	ass of sec	urities benef	icially ow	ned dir	ectly c	or indirectly.			

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Torley Helen - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amou Underlying Securi (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amo Num Shar
Option to Purchase Common Stock	\$ 18.41	02/14/2018		A	201,552	02/14/2019(1)	02/14/2028	Common Stock	201
Restricted Stock Units	\$ 0	02/14/2018		А	114,918	02/14/2019(2)	(2)	Common Stock	114

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Torley Helen C/O HALOZYME THERAPEUTICS, INC. 11388 SORRENTO VALLEY ROAD SAN DIEGO, CA 92121	Х		President and CEO				
Signatures							
/s/ James R. Oehler as attorney-in-fact for He Torley	02/16/2018						
** Signature of Reporting Person		D	ate				

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option vests one-fourth on such date and then 1/48th monthly thereafter.
- (2) This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.